Anatomical Landmark-guided Suprascapular Nerve Block ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
149. Hemiconvulsion hemiplegia epilepsy syndrome
Clinical trials : 25 / Drugs : 35 - (DrugBank : 13) / Drug target genes : 16 - Drug target pathways : 22
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05260125 (ClinicalTrials.gov) | March 15, 2022 | 18/2/2022 | Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients | Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients With Hemiplegic Shoulder Pain. | Hemiplegia;Stroke | Drug: Ultrasound-guided Suprascapular Nerve Block;Drug: Anatomical Landmark-guided Suprascapular Nerve Block | Abant Izzet Baysal University | NULL | Recruiting | 25 Years | 75 Years | All | 50 | Phase 4 | Turkey |